70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

By F. Cardoso, L. V. van’t Veer, J. Bogaerts, L. Slaets, G. Viale, S. Delaloge, J. Pierga, E. Brain, S. Causeret, Mauro Delorenzi and 24 more. New England Journal of Medicine, 2016

1,600 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2d15304b7a12d85b2b5e30dc729df4dd48d93500

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Weaver
2. Momin M. Malik
3. D. Winchester
4. J. Connolly
5. L. Solin
6. E. Mittendorf

Citations in the corpus

• Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2017, methodology): “The eighth edition expert panel formulated their recommendations before the publication of an additional prospective randomized study using a 70-gene signature (MammaPrint) to evaluate the impact of chemotherapy on women deemed to be at high risk of metastases because of clinical factors but found t”
• A Hierarchy of Limitations in Machine Learning (2020, positive): “I do include several examples of mixed methods overcoming the limitations of machine learning alone (e.g., Patton et al., 2019a; Cardoso et al., 2016, respectively for validating lived experience and experimental validation).”
• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (2018, neutral): “Negative 28/1583 (2) 267/3339 (8) 251/3240 (8) 405/1353 (30)”